Lupin: Glad To Have Dodged Humira Bullet, Lucentis Biosimilar Closer As Phase III Trials Succeed
Amazon, Mark Cuban Not Upset US Market Dynamics
Executive Summary
Lupin’s CEO highlights market access strategy as a key tool to ensure biosimilars success in the US while being relieved the company didn’t launch a Humira biosimilar. She also mentions Amazon and Mark Cuban have not upset market dynamics for generics in the US and a Lucentis biosimilar is closer to a global launch post Phase III trial success